Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Howarth

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
The European Respiratory Journal|August 21, 2020
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysisTim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, et al.
Frontiers in Immunology|May 1, 2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES studyIan Pavord, Frances Gardiner, Liam G Heaney, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 28, 2023
Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low StatusHitasha Rupani, Mohammed Aref Kyyaly, Adnan Azim, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 18, 2021
Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomesWei Chern Gavin Fong, Adnan Azim, Deborah Knight, et al.
Respiratory Research|February 9, 2021
Correction to: Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthmaNazanin Zounemat Kermani, Woo-Jung Song, Yusef Badi, et al.
Respiratory Research|January 8, 2021
Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthmaNazanin Zounemat Kermani, Woo-Jung Song, Yusef Badi, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 26, 2022
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe AsthmaCharles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2026
Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 StudiesMichael E Wechsler, Ian D Pavord, Reynold A Panettieri, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 17, 2021
The Clinical Implications of Aspergillus Fumigatus Sensitization in Difficult-To-Treat Asthma PatientsHeena Mistry, Hilda Maria Ajsivinac Soberanis, Mohammad Aref Kyyaly, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
The European Respiratory Journal|August 21, 2020
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysisTim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, et al.
Frontiers in Immunology|May 1, 2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES studyIan Pavord, Frances Gardiner, Liam G Heaney, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 28, 2023
Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low StatusHitasha Rupani, Mohammed Aref Kyyaly, Adnan Azim, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 18, 2021
Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomesWei Chern Gavin Fong, Adnan Azim, Deborah Knight, et al.
Respiratory Research|February 9, 2021
Correction to: Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthmaNazanin Zounemat Kermani, Woo-Jung Song, Yusef Badi, et al.
Respiratory Research|January 8, 2021
Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthmaNazanin Zounemat Kermani, Woo-Jung Song, Yusef Badi, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 26, 2022
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe AsthmaCharles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2026
Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 StudiesMichael E Wechsler, Ian D Pavord, Reynold A Panettieri, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 17, 2021
The Clinical Implications of Aspergillus Fumigatus Sensitization in Difficult-To-Treat Asthma PatientsHeena Mistry, Hilda Maria Ajsivinac Soberanis, Mohammad Aref Kyyaly, et al.
Pageof 11